Bioponic Phytoceuticals Treats Malaria in Africa
Bioponic Phytoceuticals launched Curemisinin for the treatment of malaria in Guinea, Africa. Bioponic, an innovative provider of natural products and patented technology serving the Complementary Alternative Medicine (CAM) and nutraceutical markets, announced the launch of Curemisinin, an all natural anti-malaria product that is based on three proven effective anti-malaria herbs: artemesia, turmeric and cinchona bark, uniquely extracted through the company’s proprietary extraction/distillation technologies. This binary product comprises a nasal spray (Curemisinin A) with an oral spray (Curemisinin B) to treat malaria in the quickest, most effective manner. Malaria is a disease caused by a blood parasite transmitted by mosquitoes. It is the number one killer in sub-Saharan Africa, killing more than a million people worldwide every year. The majority of those who die from malaria are African children, according to the Centers for Disease Control. Through Bioponic’s international alliance with Hyperdynamics Corp, Curemisinin is currently being disseminated free of charge in clinics located in the capital city of Guinea.